Answers are grounded in this paper and cite their sources.
Immune heterogeneity and metabolic remodeling frequently limit the efficacy of immunotherapy in lung adenocarcinoma (LUAD). To address this challenge, we integrated single-cell and bulk RNA sequencing analyses, pairing machine learning with preclinical models to develop the APOA5-correlated T-cell Signature (ACTsig), which effectively stratifies LUAD patients and predicts immunotherapeutic response. Moreover, We identified apolipoprotein A-V (APOA5) as a previously unrecognized tumor suppressor linking cholesterol homeostasis to the tumor immune ecosystem. Mechanistically, APOA5 deficiency induced intracellular cholesterol accumulation and MIF production. Cholesterol depletion and replenishment established a causal role for cholesterol accumulation in regulating MIF production, while MIF knockdown reversed APOA5-loss-induced T-cell exhaustion and recombinant MIF restored the phenotype. Meanwhile, CXCR4 blockade rescued APOA5-loss-induced T-cell exhaustion, supporting the functional involvement of the MIF receptor CXCR4 in this immunosuppressive phenotype. Finally, in silico drug screening identified fenofibrate, which, in combination with anti-PD-1 therapy, significantly suppressed tumor growth in APOA5-deficient models. Together, these findings establish ACTsig as a predictive biomarker for immunotherapy response and reveal an APOA5-cholesterol-MIF-CXCR4 axis underlying T-cell exhaustion.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: